Methods of treating cea-positive cancers using pd-1 axis binding antagonists and anti-cea/anti-cd3 bispecific antibodies
AssigneeHoffmann-La Roche Inc.
InventorsMarina Bacac, Sara Colombetti, Christian Klein, Johannes Sam, Jose Saro, Pablo Umana
Life of this patent
Estimating the term…
Abstract
The invention provides compositions and methods for treating CEA-positive cancers. The method comprising administering a PD-1 axis binding antagonist and a bispecific antibody that targets CEA and CD3.
Claims74
A method for treating or delaying progression of cancer in an individual comprising administering to the individual an effective amount of a human PD-1 axis binding antagonist and an anti-CEA/anti-CD3 antibody.
A method of enhancing immune function in an individual having cancer comprising administering an effective amount of a PD-1 axis binding antagonist and an anti-CEA/anti-CD3 bispecific antibody.
(canceled)
(canceled)
(canceled)
(canceled)
A kit comprising a medicament comprising a PD-1 axis binding antagonist and an optional pharmaceutically acceptable carrier, and a package insert comprising instructions for administration of the medicament in combination with a composition comprising an anti-CEA/anti-CD3 bispecific antibody and an optional pharmaceutically acceptable carrier for treating or delaying progression of cancer in an individual.
A kit comprising a first medicament comprising a PD-1 axis binding antagonist and an optional pharmaceutically acceptable carrier, and a second medicament comprising an anti-CEA/anti-CD3 bispecific antibody and an optional pharmaceutically acceptable carrier.
A kit comprising a medicament comprising an anti-CEA/anti-CD3 bispecific antibody and an optional pharmaceutically acceptable carrier, and a package insert comprising instructions for administration of the medicament in combination with a composition comprising a PD-1 axis binding antagonist and an optional pharmaceutically acceptable carrier for treating or delaying progression of cancer in an individual.
Dependencies are inferred from the claim text.